The peptide revolution is here: Get ahead of the curve as new rules look set to turn once-radical ‘miracle’ treatments mainstream

The peptide revolution started in small corners of the internet – wellness girlies promoting the next product to make your face glow or fitness bros using it to enhance their physique, but new regulations have pushed them into the mainstream.
Health and Human Services (HHS) Secretary Robert F Kennedy Jr issued new guidelines for peptides at the end of October, allowing pharmacies to distribute six peptides despite the fact that they have not been approved by the Food and Drug Administration.
Peptides are building blocks of proteins that the body can make on its own using amino acids in food, or that can be produced in a lab for medications.
Insulin, endorphins and growth hormones are examples of peptides produced in the human body. Medications like injectable insulin for diabetes and GLP-1s are FDA-approved.
However, most injectable wellness peptides sold online are not FDA-approved and are largely unregulated.
Kennedy’s new policy now allows specific pharmacies to sell and produce peptides without FDA regulation, arguing it will make products more accessible to the public through a safer distribution environment.
Professor Ana Santos Rutschman, a health law professor at Villanova University, warned that the new directive does not mean consumers can now access these peptides at pharmacies like CVS.
‘There are many peptides that are used as drugs, and those have been studied, vetted by the FDA, vetted by other regulators abroad,’ Rutschman said in an interview with the Daily Mail.
Health and Human Services Secretary Robert F Kennedy Jr issued new guidelines on wellness peptides in October
She explained that the new peptides outlined in Kennedy’s policy have not been studied and may have risks.
‘And also, the kinds of pharmacies that we’re talking about, it’s not CVS. It’s small places, specialized places that are regulated but not very tightly regulated,’ Rutschman added.
The policy only allows compounding pharmacies to manufacture and prescribe the wellness peptides.
These pharmacies are specialized and exist to tailor or combine medications to meet an individual patient’s needs. Physicians may use them if a patient is allergic to, or cannot take, a component of a standard drug produced by pharmaceutical companies.
‘That’s what these pharmacies were designed to do, and in order to do this, you just relax the law a little bit,’ Rutschman explained.
‘But basically, where they [compounding pharmacies] get the stuff from, more often than not it’s China; none of that gets inspected or very stringently regulated.’
‘If the product comes in and is contaminated with something, or if it does nothing like what the seller says it is going to do, if it’s not efficacious at all, there’s nobody looking at that, and that’s the greatest risk with these pharmacies,’ Rutschman explained.
The HHS Secretary has long supported peptides, citing them as part of the Make America Healthy Again agenda.
Professor Ana Santos Rutschman told the Daily Mail that the FDA uses ‘enforcement discretion’ on wellness peptides, meaning they can regulate them but have chosen not to
The new guidance applies ‘enforcement discretion’ to the distribution of these six peptides, meaning that although the FDA has the authority to regulate them, it has chosen not to.
Rutschman explained that multiple federal agencies use enforcement discretion. The FDA has previously used enforcement discretion during drug shortages to allow compounding pharmacies to produce the drug.
The FDA used to practice enforcement discretion on medical products. That is part of why the agency did not monitor the infamous blood-testing product developed by Theranos, which led to Elizabeth Holmes’s imprisonment for her false claims.
The new policy grants pharmacists the ability to compound six peptides, including BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.
Combining BPC-157 and TB-500 has been nicknamed the ‘wolverine’ stack because it is marketed to help with muscle repair.
Dr Omar Rahman, an orthopedic surgeon who has studied peptides, told the Daily Mail that he has clinical experience with BPC-157 and TB-500, which both have data to support that they can help with tendon healing, tissue repair and angiogenesis.
MOTS-c has also been used by athletes to support recovery, while KPV has been known to support inflammation and Semax has been used for focus and cognition.
These peptides are already available to the public through online retailers and select wellness shops.
Two doctors told the Daily Mail that Kennedy’s new policy directive may make these peptides safer, but still come with risks
For example, the company American Peptides has a BPC-157 and TB-500 blend, or the ‘wolverine stack,’ for $195.
Rahman also noted that several Chinese suppliers sell the wellness peptides. He noted that Kennedy’s policy could make consumption safer because consumers would need a prescription and the product would be made in a controlled environment by a licensed pharmacist.
Dr Frank Agullo, a plastic surgeon and clinical associate professor at Texas Tech University, told the Daily Mail that he has seen skin infections and abscesses in patients who purchased an injectable peptide online marketed as ‘for research purposes only.’
He noted that pharmacies have higher production standards, and adding a prescription to the equation could make use safer.
However, Agullo added that the wellness peptides listed in the policy are still not regulated by the FDA.
‘A pharmacy shelf is not a clinical trial. This policy may make these peptides cleaner and safer to buy, but it does not make them proven, and I worry many patients will not see the difference,’ he said.
Rutschman added that since these peptides are now more accessible, she worries the incentive has disappeared for meaningful clinical trials to take place.
‘If you have this kind of regulatory regime in place, then it kind of kills the incentives unless somebody out of sheer goodwill wants to do it,’ she said.
The HHS has argued that the new policy protects patient safety while still advocating for choice.
A spokesperson for the department said the policy requires ‘patient-specific prescriptions, traceable ingredients, quality testing and safety reporting to hold compounders accountable and give patients an alternative to unregulated sellers.’
The statement added that the policy confronts the risks posed by black-market sellers. The Daily Mail has reached out to the HHS for additional comment.
